Key result
SARS-CoV-2 ORF6 requires methionine M58 to bind Rae1-Nup98 and block nucleocytoplasmic transport.
Why the study?
SARS-CoV-2 variants of concern show elevated expression of the viral accessory protein ORF6, a potent interferon antagonist whose structural mechanism in blocking nucleocytoplasmic transport was not fully defined.
The study reveals the structural basis of how SARS-CoV-2 ORF6 antagonizes interferon signaling by binding the Rae1-Nup98 complex via an essential M58 residue, identifying a potential target for drug development.
Answers are grounded in this paper and cite their sources.
M58 offers a structural antiviral target in ORF6; leaves open whether its disruption restores interferon signaling or attenuates infection in vivo.
The emergence of heavily mutated SARS-CoV-2 variants of concern (VOCs) place the international community on high alert. In addition to numerous mutations that map in the spike protein of VOCs, expression of the viral accessory proteins ORF6 and ORF9b also elevate; both are potent interferon antagonists. Here, we present the crystal structures of Rae1-Nup98 in complex with the C-terminal tails (CTT) of SARS-CoV-2 and SARS-CoV ORF6 to 2.85 Å and 2.39 Å resolution, respectively. An invariant methionine (M) 58 residue of ORF6 CTT extends its side chain into a hydrophobic cavity in the Rae1 mRNA binding groove, resembling a bolt-fitting-hole; acidic residues flanking M58 form salt-bridges with Rae1. Our mutagenesis studies identify key residues of ORF6 important for its interaction with Rae1-Nup98 in vitro and in cells, of which M58 is irreplaceable. Furthermore, we show that ORF6-mediated blockade of mRNA and STAT1 nucleocytoplasmic transport correlate with the binding affinity between ORF6 and Rae1-Nup98. Finally, binding of ORF6 to Rae1-Nup98 is linked to ORF6-induced interferon antagonism. Taken together, this study reveals the molecular basis for the antagonistic function of Sarbecovirus ORF6, and implies a strategy of using ORF6 CTT-derived peptides for immunosuppressive drug development.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2022) studied SARS-CoV-2 infection. SARS-CoV-2 ORF6 CTT peptides was evaluated on Binding affinity to Rae1-Nup98 complex. Structural analysis reveals that an invariant methionine (M58) in the SARS-CoV-2 ORF6 C-terminal tail is essential for binding the Rae1-Nup98 complex and blocking nucleocytoplasmic transport.
Synapse has enriched 10 related papers. Consider them for comparative context: